Holen Sie sich die Stockscreener-App
9.41
1.88%
-0.18
Handel nachbörslich:
9.59
0.18
+1.91%
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart.com
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - GuruFocus
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative
Corbus Pharmaceuticals: Q4 Earnings Snapshot - WWLTV.com
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
Corbus Pharmaceuticals (NASDAQ: CRBP) widens 2025 loss but boosts cash and pipeline progress - Stock Titan
Income Plays: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveMarket Movement Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Buyout Rumor: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - MarketBeat
Insider sale notice — CRBP (NASDAQ: CRBP) lists 12,500 RSUs - Stock Titan
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Aug Movers: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rateJuly 2025 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
Fund Flows: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rate2025 Buyback Activity & Fast Momentum Stock Entry Tips - baoquankhu1.vn
CRBP Should I Buy - Intellectia AI
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. advances CRB-701 for Nectin-4 solid tumors in early-stage development - Traders Union
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead - MarketBeat
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook - TipRanks
EDGAR Filing Documents for 0001193125-26-068566 - SEC.gov
Corbus updates corporate presentation, details 2026 clinical and financial milestones - TradingView
Corbus Pharmaceuticals (CRBP) highlights oncology and obesity pipeline progress - Stock Titan
CRBP News Today | Why did Corbus Pharmaceuticals stock go up today? - MarketBeat
Chart Watch: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group - Defense World
Corbus (CRBP) CEO Yuval Cohen sells shares in Rule 10b5-1 tax-cover transaction - Stock Titan
(CRBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Working capital per share of Corbus Pharmaceuticals Holdings Inc – LSE:0SZI - TradingView
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
[144] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
Decliners Report: What is Corbus Pharmaceuticals Holdings Incs revenue forecastJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - Bitget
Corbus Pharmaceuticals to Present at 36th Annual Oppenheimer Healthcare Life Sciences Conference - Quiver Quantitative
Can Corbus Pharmaceuticals Holdings Inc. maintain its current growth rateQuarterly Earnings Summary & AI Driven Stock Price Forecasts - mfd.ru
Stock Recap: What is the cash position of Corbus Pharmaceuticals Holdings IncQuarterly Profit Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Published on: 2026-02-11 16:50:32 - mfd.ru
Should I hold or sell Corbus Pharmaceuticals Holdings Inc. stock in 2025July 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Published on: 2026-02-08 12:15:37 - baoquankhu1.vn
Responsive Playbooks and the CRBP Inflection - Stock Traders Daily
Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms - Seeking Alpha
Forecast Cut: What dividend growth rate does Corbus Pharmaceuticals Holdings Inc offerJuly 2025 Intraday Action & Weekly Setup with ROI Potential - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):